Pan African Clinical Trials Registry

South African Medical Research Council, South African Cochrane Centre
PO Box 19070, Tygerberg, 7505, South Africa
Telephone: +27 21 938 0506 / +27 21 938 0834 Fax: +27 21 938 0836
Email: pactradmin@mrc.ac.za Website: pactr.samrc.ac.za
Trial no.: PACTR202001558172073 Date of Approval: 21/01/2020
Trial Status: Registered in accordance with WHO and ICMJE standards
TRIAL DESCRIPTION
Public title Influence of LASER therapy and Ultra-violent radiation on the treatment of diabetic foot
Official scientific title Comparison of LASER and Ultra-violent radiation on the treatment of diabetic foot and patients' quality of life
Brief summary describing the background and objectives of the trial Diabetic foot syndrome as a chronic complication of Diabetes mellitus is a major therapeutic challenge. It has a high financial impact and a severe effect on the patients’ quality of life and can even lead to limb amputation. Phototherapy is a noninvasive, pain-free method with minor side effects, has been considered as a possible treatment option for the diabetic foot syndrome. The objective of this to compare the effectiveness of LASER therapy and Ultra violent radiation on diabetic foot and patients' quality of life.
Type of trial RCT
Acronym (If the trial has an acronym then please provide)
Disease(s) or condition(s) being studied Nutritional, Metabolic, Endocrine,Skin and Connective Tissue Diseases
Sub-Disease(s) or condition(s) being studied
Purpose of the trial Treatment: Devices
Anticipated trial start date 10/01/2020
Actual trial start date 10/01/2020
Anticipated date of last follow up 03/04/2020
Actual Last follow-up date 17/04/2020
Anticipated target sample size (number of participants) 60
Actual target sample size (number of participants) 45
Recruitment status Not yet recruiting
Publication URL
Secondary Ids Issuing authority/Trial register
HMB GEN 601 VOL 490 KANO STATE HOSPITAL MANAGEMENT BOARD ETHICS COMMITEE
STUDY DESIGN
Intervention assignment Allocation to intervention If randomised, describe how the allocation sequence was generated Describe how the allocation sequence/code was concealed from the person allocating the participants to the intervention arms Masking If masking / blinding was used
Crossover: all participants receive all interventions in different sequence during study Randomised Simple randomization using a randomization table created by a computer software program Sealed opaque envelopes Masking/blinding used Care giver/Provider,Outcome Assessors,Participants
INTERVENTIONS
Intervention type Intervention name Dose Duration Intervention description Group size Nature of control
Experimental Group LLLT GROUP 3 TIMES A WEEK 30 MONUTES The participants will receive LASER therapy treatment 3times per together with standard wound care consisting of wound cleaning twice daily, application of moist dressings, and continuous relief of pressure until the wounds were healed.with the conventional dressing. 20
Experimental Group UVR EXPERIMENTAL GROUP 3TIMES PER WEEK 30 MINUTES The participants will receive UVR on their wound 3times a week together with standard wound care consisting of wound cleaning twice daily, application of moist dressings, and continuous relief of pressure until the wounds were healed. 20
Control Group Control group twice daily 30 minutes The participants of this group will receive standard wound care consisting of wound cleaning twice daily, application of moist dressings, and continuous relief of pressure until the wounds were healed. 20 Active-Treatment of Control Group
ELIGIBILITY CRITERIA
List inclusion criteria List exclusion criteria Age Category Minimum age Maximum age Gender
1)Provision of signed and dated informed consent form 2)Male or Female 3)Age:18-90 years old at the time of Informed Consent (Adult, Senior) 4)Type 1 or type 2 Diabetes Mellitus 5)Presence of a diabetic foot ulcer located in the ankle area or below that has persisted a minimum of 3 months prior to the screening visit 6) Ulcer grade classified as ≤3 according to Wagner grading system or IA according to University of Texas Classification of Diabetic Foot Ulcers. 7) Area of ulcer (after debridement) is at least 4 cm2 8) Arterial perfusion: Patients who demonstrate adequate arterial perfusion defined as either: Ankle/brachial index (ABI) above 0.7 or that have documented confirmation of adequate arterial perfusion 9) For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation 1) Pre-existing conditions - evidence of gangrene on any part of affected limb, active Charcot's foot on the study limb; infection at time of screening, deep vein thrombosis (DVT), active malignancy, being on dialysis, anemia (Hb<9 gr/dL) 2) Known allergies to dressing materials, including occlusive dressings and the adhesives on such dressings Scheduled to undergo vascular surgery, angioplasty or thrombolysis at the time of enrollment or history of peripheral vascular repair within 10 weeks of screening 3) History of malignancy on study limb or currently receiving or has received radiation or chemotherapy within 3 months of randomization 4) Taking immunosuppressive medication 5) Received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening 6) Used oral, or IV antibiotic/antimicrobial agents or medications within 7 days of baseline 7) Has serum albumin level of<3 mg% 8) Presence of ulcers due to other causes not related to diabetes 9) HbA1c > 12% (uncontrolled hyperglycemia) 10)Pregnant at the time of screening 11) Has any photobiomodulation (low level laser) device at home 80 and over: 80+ Year,Adult: 19 Year-44 Year,Aged: 65+ Year(s),Middle Aged: 45 Year(s)-64 Year(s) 18 Year(s) 90 Year(s) Both
ETHICS APPROVAL
Has the study received appropriate ethics committee approval Date the study will be submitted for approval Date of approval Name of the ethics committee
Yes 20/10/2019 Kano State Hospital management baord Ethics Commitee
Ethics Committee Address
Street address City Postal code Country
Post Office Road, kano kano 00234 Nigeria
OUTCOMES
Type of outcome Outcome Timepoint(s) at which outcome measured
Primary Outcome wound closure baseline, 6week, and 12weeks
Secondary Outcome quality of life baseline, 6week, and 12weeks
RECRUITMENT CENTRES
Name of recruitment centre Street address City Postal code Country
Murtala Mohammed Specialist Hospital Old city road Kano Kano 00234 Nigeria
Abdullahi wase specialist Hospital Old city Road Kano Kano 00234 Nigeria
FUNDING SOURCES
Name of source Street address City Postal code Country
Dr. Abdulsalam Mohammed Yakasai 1 katsina road kano, federal government secreteriat complex, kano state. Kano Nigeria
SPONSORS
Sponsor level Name Street address City Postal code Country Nature of sponsor
Primary Sponsor Dr. Abdulsalam Mohammed Yakasai 1 Katsina Road kano. kano Nigeria Individual
COLLABORATORS
Name Street address City Postal code Country
Dr. Jibril Nuhu Hospital road, Kano Kano Nigeria
Umar Hadi Hospital road, Kano Kano Nigeria
CONTACT PEOPLE
Role Name Email Phone Street address
Principal Investigator ABDULSALAM MOHAMMED YAKASAI abdulpeace1@gmail.com +2348060840806 1 katsina road, kano.
City Postal code Country Position/Affiliation
kano Nigeria Head Kano Zonal office Medical Rehabilitation Therapists Board of Nigeria
Role Name Email Phone Street address
Scientific Enquiries Jibril Nuhu jibrilnuhu702@gmail.com +2348066723572 Hospital road
City Postal code Country Position/Affiliation
Kano Nigeria Head of the research Team
Role Name Email Phone Street address
Public Enquiries ABDULLAHI MOHAMMED MAHMUD bmrec@kshmb.gov.ng +2348054444447 post office road
City Postal code Country Position/Affiliation
kano Nigeria Head ethics committee
REPORTING
Share IPD Description Additional Document Types Sharing Time Frame Key Access Criteria
Yes We are going to share the data of the present study after analysis when requested. Informed Consent Form,Statistical Analysis Plan,Study Protocol The documents of our study would be shared as soon as we analyzed the data. The data will be given to the research members and others research fellows on request, and the row data will be destroyed after 5 years of complition of the study.
URL Results Available Results Summary Result Posting Date First Journal Publication Date
No
Result Upload 1: Result Upload 2: Result Upload 3: Result Upload 4: Result Upload 5:
Result URL Hyperlinks Link To Protocol
Result URL Hyperlinks
Changes to trial information